Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says
(Reuters) Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company’s revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes and autoinjectors.

The German company reported in February that it expects to grow an average of 10% per year. Nearly half of that will come from its association with drugs in the GLP-1 class, the CEO told Reuters. Novo Nordisk’s popular obesity drug Wegovy and Eli Lilly’s in demand Zepbound are GLP-1 drugs.

Siemssen said he expects sales related to GLP-1 medicines to surpass 100 million euros this year and to reach at least 350 million euros ($379 million) within the next three years, based on actual contracts and orders.

“We are just at the beginning of the ramp up towards the total market for (these drugs), and the biggest growth you will see from 2025 to 2027,” he said.

Two analysts contacted by Reuters said they expect Wegovy on average to bring in sales of about $8.6 billion this year and $12.86 billion in 2025.